… for the bronchodilator effect, and (S)-albuterol, which … albuterol with placebo in patients
with moderate-to-severe asthma. Methods: This was a randomized, double-blind, parallel-group …

… or symptomatic bronchodilator treatment. Within each of these parallel groups we randomly
… Patients with continuous bronchodilator therapy may tolerate precipitating situations better, …

… Combination bronchodilator therapy for chronic obstructive … anticholinergic therapy with
sympathomimetic therapy in … -blind, parallelgroup evaluation of the use of the following: albuterol, …

… is dosed BID it is likely that the bronchodilator efficacy of GB would be greater than tiotropium
… The bronchodilator effects of inhaled glycopyrronium have been studied using both once …

… does not preclude subsequent benefit from maintenance bronchodilator therapy.14, 34
Thus, current guidelines no longer recommend using reversibility testing with a short-acting …

… peak flow measurements, symptom scores, and bronchodilator use for at least 2 weeks. At …
from short acting bronchodilator inhalers for 4 hours, long acting bronchodilators for 12 hours, …

… Inhaled corticosteroids (ICSs) are added to bronchodilator therapy because of their
ability to deliver the antiinflammatory medication directly to the site of inflammation (4). …

… Randomized trials of triple therapy including an inhaled … dual bronchodilators, likely resulting
from ICS withdrawal at randomization. We compared triple therapy with dual bronchodilator …

… bronchodilator groups … therapy with initiators of dual bronchodilators after weighting by fine
stratification of propensity scores and averaging over the two strata, show that the two groups …

Full article: Clinical benefit of fixed-dose dual bronchodilation with glycopyrronium and
indacaterol once daily in patients with chronic obstructive pulmonary disease: a systematic …